Effects of IFN-.gamma. on cardiac hypertrophy
US6187304A · kind A · utility
6Cited by
12References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 1999 |
| Grant date | Feb 13, 2001 |
| Priority date | — |
| Expiry date | Mar 19, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-.gamma.). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.